A development process is a structured sequence of steps that takes an idea from its earliest form to a finished, usable result. Whether you’re building software, bringing a drug to market, designing a physical product, or conducting scientific research, the underlying logic is the same: define what you want to create, plan how to create it, build and test it, then refine and release it. The specifics vary widely by field, but every development process exists to reduce risk, catch problems early, and turn something abstract into something real.
The Core Pattern Behind Every Development Process
Despite surface differences, nearly all development processes share a common skeleton. They begin with an idea or problem worth solving, move through planning and design, enter a building or experimentation phase, pass through testing and validation, and end with release, launch, or implementation. After that, most loop back into monitoring and improvement.
This pattern holds whether you’re a pharmaceutical company spending years on a new medication or a startup building an app in a few months. The reason every industry gravitates toward a structured process is simple: skipping steps is expensive. A software bug caught during testing costs a fraction of what it costs after launch. A drug safety issue caught in animal studies prevents a failed human trial that could waste hundreds of millions of dollars. The process is, at its core, a way of failing cheaply and early rather than expensively and late.
Product Development: Concept to Market
In the broadest sense, product development follows six stages: ideation, product definition, prototyping, design, testing, and commercialization. During ideation, teams generate and filter new concepts. Product definition narrows down what the product will actually do, who it’s for, and what success looks like. Prototyping creates a rough version to test assumptions before committing to full production.
Design refines the prototype into something polished and manufacturable. Testing puts it through quality checks, user feedback rounds, and performance benchmarks. Commercialization is the final push: manufacturing at scale, marketing, distribution, and launch. Each stage acts as a gate. If the product doesn’t hold up at one stage, teams go back and fix the problem before moving forward rather than discovering it after customers are already using it.
Software Development Life Cycle
Software follows its own version called the Software Development Life Cycle, or SDLC, which typically includes seven stages: planning and requirement analysis, defining requirements, designing architecture, coding, testing, deployment, and maintenance. The planning phase identifies what the software needs to do and what resources it will take. Requirements get documented in detail so developers know exactly what to build. Architecture design maps out how different parts of the system will connect.
Coding is the actual construction phase, followed by testing to catch bugs, security holes, and performance issues. Deployment makes the software available to users. Maintenance is ongoing: fixing problems, releasing updates, and adapting to new needs. Unlike a physical product that ships once, software often cycles through these stages repeatedly for years after its initial release.
Waterfall vs. Agile Approaches
Two major philosophies shape how teams move through these stages. The waterfall approach treats each phase as sequential: you finish one completely before starting the next. It works well when requirements are clearly defined upfront and unlikely to change, like building software to meet a specific regulatory standard.
Agile methods, by contrast, break the work into short cycles (usually one to four weeks) and repeat the build-test-learn loop rapidly. Large-scale evidence now supports that agile methods outperform traditional waterfall approaches across all sizes of software projects, particularly in complex situations where the ideal solution isn’t clear at the start. Agile has expanded well beyond software into healthcare innovation, electronic health record systems, and general product development.
Drug Development: Lab to Pharmacy
Few development processes are as long, expensive, or rigorous as pharmaceutical drug development. The FDA outlines five major steps: discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring.
Discovery starts in a laboratory, where researchers identify compounds that might treat a disease. Preclinical research tests those compounds in lab settings and animal models to answer basic safety questions before any human is exposed. Clinical research is where a drug is tested in people, progressing through three phases of trials that expand from small safety studies to large trials involving thousands of patients.
The numbers are sobering. Roughly 90% of drug candidates fail during clinical development. Between 2016 and 2020, only 29 to 34% of drugs passed Phase II trials (which test whether a drug actually works), while 70 to 73% passed Phase III (which confirms effectiveness in larger groups). The clinical phase alone lasts an average of about 95 months, nearly eight years, and accounts for 69% of total research and development costs. The average out-of-pocket cost per approved drug has been estimated at $172.7 million, but after factoring in the cost of all the failed candidates and the capital tied up over those years, the total reaches roughly $879 million per successful drug.
Once approved, the process still isn’t over. The FDA continues monitoring a drug’s safety after it reaches the public, watching for rare side effects that only become visible when millions of people are taking it.
Medical Device Development
Medical devices follow a separate regulatory path that depends on how much risk the device poses. The FDA sorts devices into three classes. Class I devices (like bandages or tongue depressors) carry the lowest risk and face the lightest requirements. Class II devices (like powered wheelchairs or pregnancy tests) are moderate risk and typically require a 510(k) submission, which means the manufacturer must show the new device is substantially equivalent to one already on the market in terms of intended use, technology, and performance.
Class III devices are the highest risk category: things that sustain or support life, are implanted in the body, or present a potential for serious harm. These require a Premarket Approval (PMA), the most demanding type of submission. The manufacturer must provide valid scientific evidence, often including clinical trial data, demonstrating both safety and effectiveness. The development process for a Class III device can take years of testing and millions of dollars, while a low-risk Class I device might reach the market with minimal regulatory friction.
The Scientific Method as a Development Process
Scientific research follows its own development process, and it’s one most people learned in school: make an observation, ask a question, form a hypothesis, make a prediction, test it, and use the results to refine or replace your hypothesis. What makes this a true development process rather than just a checklist is that it’s iterative. The result of one cycle becomes the starting point for the next.
Results that support a hypothesis don’t conclusively prove it correct, but they make it more likely. Results that contradict the hypothesis suggest it’s probably wrong and needs revision. This built-in self-correction is what separates the scientific method from less structured approaches to problem-solving, and it’s the same principle that drives every other development process: build, test, learn, repeat.
Why the Process Matters More Than the Product
The common thread across all of these examples is that a development process exists to manage uncertainty. At the start of any project, you don’t know everything: which features users actually want, whether a drug compound is safe, whether your device will perform reliably, or whether your hypothesis is correct. Each stage of the process is designed to answer specific unknowns before you invest more time and money.
Skipping stages doesn’t save time in the long run. It shifts risk downstream, where problems are harder and more expensive to fix. A software team that skips requirement analysis builds the wrong thing. A drug company that rushes past preclinical research endangers human trial participants. A product team that skips prototyping discovers manufacturing problems after tooling is already built. The process is the discipline that turns creative ambition into something that actually works.